<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-155735" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Urinary Crystals Identification and Analysis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simhadri</surname>
            <given-names>Prathap Kumar</given-names>
          </name>
          <aff>Advent Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prathap Kumar Simhadri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-155735.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Urinary crystal formation is a marker of urinary supersaturation with various substances. Crystals can occur secondary to inherited diseases, metabolic disorders, and medications. The presence of crystals in the urine is not always pathognomic for an abnormal metabolic or renal condition, as uric acid, calcium oxalate, calcium phosphate (CaP), and drug-induced crystals can also be&#x000a0;observed&#x000a0;under normal physiological conditions. The diagnosis of various monogenetic diseases, such as cystinuria, primary hyperoxaluria, and adenine phosphoribosyl transferase deficiency, can be suggested by examining the urinary sediment and correct identification of the&#x000a0;associated urinary crystals.</p>
        <p>Urinary crystal formation always precedes renal stone formation but does not always lead to nephrolithiasis. When kidney stones are formed, they have the potential to cause acute kidney injury, obstructive uropathy, hydronephrosis, renal colic, pyonephrosis, and urosepsis. Urinary crystals can also cause renal crystal deposition disease, resulting in&#x000a0;acute kidney injury, progressive chronic kidney disease, and end-stage kidney disease.</p>
        <p>Urine sediment examination can be considered a liquid biopsy of the kidney because it provides valuable information about the events occurring in an individual's kidney. However, with the increased utilization of automated systems, urine sediment examination is becoming a lost art. Nonetheless, it remains an excellent source of clinical information to help appropriately diagnose and manage patients with various diseases associated with urinary crystal formation. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/154870">Calcium Deposition and Other Renal Crystal Diseases</ext-link>," for more information.</p>
      </sec>
      <sec id="article-155735.s2" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>Metabolic factors, inherited diseases, medications, dietary habits, dehydration, and anatomical abnormalities are the common etiologies contributing to urinary crystal formation. Kidney stone formation is a known risk factor for developing diabetes, cardiovascular disease, fractures, and chronic renal disease. Conversely, these conditions also increase the risk of nephrolithiasis.</p>
        <p>Kidney stone disease is a polygenetic and multifactorial health problem worldwide that affects between 1% and 13% of the global population and almost 11% of the Western population.<xref ref-type="bibr" rid="article-155735.r1">[1]</xref>&#x000a0;Over the&#x000a0;past 30 years, the prevalence of kidney stones has been rising across all ages, genders, racial and ethnic groups globally. Approximately 10% of the United States population experience nephrolithiasis in their lifetime.<xref ref-type="bibr" rid="article-155735.r2">[2]</xref><xref ref-type="bibr" rid="article-155735.r3">[3]</xref></p>
        <p>Estimating the overall prevalence of urinary crystalluria is challenging, as this condition is underdiagnosed and underreported.&#x000a0;Although&#x000a0;scant literature is available on the prevalence of urinary crystalluria, several studies showed crystalluria in approximately&#x000a0;8% of urine collections.&#x000a0;Calcium oxalate, uric acid, and amorphous urate crystals accounted for most of the crystals encountered. Brushite, ammonium biurate, and cystine crystals were rare.<xref ref-type="bibr" rid="article-155735.r4">[4]</xref><xref ref-type="bibr" rid="article-155735.r5">[5]</xref><xref ref-type="bibr" rid="article-155735.r6">[6]</xref></p>
      </sec>
      <sec id="article-155735.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Urine contains both promoters and inhibitors of crystal formation. Crystallization occurs when the concentration of crystal promoters in the glomerular filtrate exceeds the kidney's ability to keep them as soluble molecules. Stone inhibitors include citrate; uromodulin, also known as Tamm-Horsfall protein; magnesium; glycosaminoglycans; and pyrophosphate. Some chemical mediators decrease&#x000a0;the urinary crystal's growth, aggregation, and adhesion to the tubular epithelium and the tubular cell; examples are&#x000a0;osteopontin, matrix Gla protein, Tamm-Horsfall protein, and urinary fragment 1 of prothrombin.<xref ref-type="bibr" rid="article-155735.r7">[7]</xref><xref ref-type="bibr" rid="article-155735.r8">[8]</xref></p>
        <p>Calcium, oxalate, urate, and phosphate ions are the leading promoters of crystal formation. Physiological factors influencing kidney stone formation include high urinary osmolarity or low urine volume, bacteria in the urinary tract, and urine pH. Structural factors influencing nephrolithiasis include urinary reflux, instrumentation, and genetic abnormalities of the urinary tract.<xref ref-type="bibr" rid="article-155735.r8">[8]</xref> Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/28339">Renal Calculi, Nephrolithiasis</ext-link>," for&#x000a0;more information.</p>
      </sec>
      <sec id="article-155735.s4" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>A first-morning&#x000a0;urine sample (void after awakening) is ideal for crystal analysis as it tends to be the most concentrated for crystal formation. The urine sample should be brought to the lab and processed within 2 hours of collection.&#x000a0;Uric acid and phosphorous crystallization can occur if the urine stays stagnant for longer than 2 hours. Refrigeration of the urine specimen is necessary after 2 hours, and examination within 8 hours of collection is recommended, even when refrigerated.<xref ref-type="bibr" rid="article-155735.r6">[6]</xref><xref ref-type="bibr" rid="article-155735.r9">[9]</xref></p>
        <p>Urine analysis through automated and manual methods can provide significant clues to the type and characteristics of urinary crystals. When examining the sediment, urine pH, specific gravity, and a dipstick analysis should always be recorded. Of note, casts degrade quickly in alkaline urine. Red blood cells (RBCs) and white blood cells (WBCs) can swell in low osmolality and shrink in high osmolality.<xref ref-type="bibr" rid="article-155735.r10">[10]</xref>&#x000a0;</p>
        <p>Urine pH plays a key role in crystallization, as CaP, struvite, and ciprofloxacin crystals precipitate in alkaline urine. In contrast, uric acid, cystine, and other drug-induced crystals tend to precipitate in acidic urine. These characteristics assist clinicians in accurately identifying urinary crystals.<xref ref-type="bibr" rid="article-155735.r6">[6]</xref></p>
        <p>For microscopic examination, 10 mL of urine should be centrifuged at 1500 to 3000 revolutions per minute for at least&#x000a0;5 min. The sediment is obtained through a pipette after discarding the top 9.5 cc of supernatant and gentle manual agitation of the test tube. A single drop of urine sediment is placed on the glass slide and covered with a cover slip for direct observation.&#x000a0;The sediment is examined using a standard brightfield or phase contrast microscope at low and high magnification. A minimum of 10 fields should be reviewed at each power.&#x000a0;The specimen is then examined under polarization to determine birefringence and identify other detailed characteristics.<xref ref-type="bibr" rid="article-155735.r6">[6]</xref>&#x000a0;</p>
        <p>Automated urinary analyzers also often miss crystals when compared to manual microscopic evaluation.<xref ref-type="bibr" rid="article-155735.r11">[11]</xref>&#x000a0;Off note, a recent study found significant interoperator variability identifying urinary sediment components, even among experienced nephrologists. Therefore, when possible, a personal examination of urine sediment is preferable.<xref ref-type="bibr" rid="article-155735.r12">[12]</xref></p>
      </sec>
      <sec id="article-155735.s5" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>A comprehensive workup is essential for diagnosing the etiology of urinary crystals. This approach includes ob<bold>t</bold>aining a&#x000a0;detailed history and performing a thorough&#x000a0;physical examination, and may also include x-ray KUB, renal&#x000a0;or abdominal ultrasound, and plain computed tomography (CT) of the abdomen and pelvis to help localize the renal stones. Simple urinalysis and analysis of the urinary crystals can help understand a stone's chemical composition. A chemical analysis of a passed stone can give a definitive answer.<xref ref-type="bibr" rid="article-155735.r7">[7]</xref><xref ref-type="bibr" rid="article-155735.r13">[13]</xref></p>
        <p>Crystalluria indicates supersaturation of the components in the urine, leading to precipitation of the crystals. However, supersaturation alone is insufficient to cause nephrolithiasis; other inciting factors are also typically present. The process can be related to metabolic disorders, inherited diseases, drug use, or toxins. The initial diagnostic test is generally a 24-hour urine collection evaluating the following parameters&#x02014;urinary volume, pH, calcium, citrate, creatinine, magnesium, phosphate, uric acid, sodium, serum calcium, oxalate, and uric acid levels. The collection should ideally be performed in nonacute conditions at the patient's home with their normal diet and fluid intake for optimal information.&#x000a0;Additional workup is typically guided by the type of crystal identified and patient history.<xref ref-type="bibr" rid="article-155735.r7">[7]</xref><xref ref-type="bibr" rid="article-155735.r8">[8]</xref><xref ref-type="bibr" rid="article-155735.r10">[10]</xref><xref ref-type="bibr" rid="article-155735.r13">[13]</xref> Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/30861">24-Hour Urine Collection</ext-link>," and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/40765">24-Hour Urine Testing for Nephrolithiasis: Interpretation and Treatment Guidelines</ext-link>,"&#x000a0;for&#x000a0;more information.</p>
        <p>
<bold>Further Diagnostic Testing Based on Stone Composition</bold>
</p>
        <p><bold>Calcium oxalate:&#x000a0;</bold>Calcium oxalate stones comprise up to 80% of all nephrolithiasis cases. Calcium oxalate and CaP often coexist in stones, but&#x000a0;1 component is typically primary. Patients with calcium oxalate crystals should&#x000a0;be considered for primary and secondary causes of hyperoxaluria. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/154870">Calcium Deposition and Other Renal Crystal Diseases</ext-link>," for more information.&#x000a0;Calcium oxalate dihydrate (COD) crystals are also highly associated with hypercalcemia, which should also be considered. Calcium oxalate crystalluria is not necessarily pathologic, as these crystals can sometimes be found in patients with high oxalate diets.<xref ref-type="bibr" rid="article-155735.r6">[6]</xref>&#x000a0;</p>
        <p>Hyperoxaluria of &#x0003e;75 mg/d&#x000a0;in a 24-hour urine collection suggests possible hereditary hyperoxaluria (types I, II, or III).</p>
        <p><bold>Calcium phosphate: </bold>CaP&#x000a0;nephrolithiasis is the second most common type, representing about 10% to 20% of kidney stones. The presence of these stones should prompt evaluation for conditions causing hypercalciuria, hyperphosphaturia, and alkaline urine formation. These crystals can also be found under normal physiological conditions.</p>
        <p><bold>Struvite:&#x000a0;</bold>Struvite comprises ammonium, magnesium, and calcium binding with phosphate (triple phosphate). The presence of struvite stones, even in lower quantities, is almost always associated with infection by urease-producing microorganisms, such as <italic toggle="yes">Proteus mirabilis</italic>,<italic toggle="yes"> Klebsiella pneumonia</italic>,<italic toggle="yes"> Staphylococcus aureus</italic>,<italic toggle="yes"> Pseudomonas aeruginosa</italic>, <italic toggle="yes"><italic toggle="yes">Providencia&#x000a0;</italic>stuartii</italic>,<italic toggle="yes"> Serratia</italic>,&#x000a0;and&#x000a0;<italic toggle="yes">Morganella morganii</italic>.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/keywords/cmeuserviewpopupwithquestions/167928?Return=%2FKeywords%2FIndex#link_34132361">[8]</ext-link></p>
        <p><bold>Uric acid:&#x000a0;</bold>Uric acid&#x000a0;dihydrate crystals primarily depend on low urine pH, whereas the amorphous ones are mainly related to high urinary urate concentration.&#x000a0;Uric acid crystals are only found when the urinary pH is acidic, as uric acid becomes much more soluble as the pH increases.<xref ref-type="bibr" rid="article-155735.r8">[8]</xref><xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref>&#x000a0;The presence of uric acid dihydrate crystals should prompt the workup for conditions causing impaired renal ammoniogenesis, such as metabolic syndrome and type 2 diabetes.<xref ref-type="bibr" rid="article-155735.r10">[10]</xref></p>
        <p><bold>Xanthine:&#x000a0;</bold>Xanthine crystals are found in xanthinuria, a rare genetic disorder with autosomal recessive pattern inheritance caused by the deficiency of the enzyme xanthine dehydrogenase. Not all laboratories can test for xanthine and hypoxanthine, nor are these part of a routine urine collection. If this rare disorder is suspected, this test must be ordered specifically. Biopsy of the gastrointestinal tract to quantify xanthine dehydrogenase is rarely performed.<xref ref-type="bibr" rid="article-155735.r15">[15]</xref>&#x000a0;An allopurinol loading test can also be used to detect a lack of xanthine oxidase, as allopurinol&#x000a0;is abnormally metabolized in patients with hereditary xanthinuria; however, these measurements may not be available in all laboratories.<xref ref-type="bibr" rid="article-155735.r16">[16]</xref> Xanthinuria is also associated with hypouricemia and hypouricosuria.<xref ref-type="bibr" rid="article-155735.r17">[17]</xref></p>
        <p>Patients with 2,8-dihydroxyadenine (DHA) crystalluria, cystinuria, and suspected primary hyperoxaluria&#x000a0;can also be genetically tested to confirm the diagnosis.<xref ref-type="bibr" rid="article-155735.r13">[13]</xref><xref ref-type="bibr" rid="article-155735.r18">[18]</xref></p>
        <p>Please see StatPearls' companion resources, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/154870">Calcium Deposition and Other Renal Crystal Diseases</ext-link>," "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/23199">Hyperoxaluria</ext-link>,"&#x000a0; "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/66949">Uric Acid Nephrolithiasis</ext-link>,"&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/29583">Struvite and Triple Phosphate Renal Calculi</ext-link>,"&#x000a0;and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/20219">Cystinuria</ext-link>,"&#x000a0;for more information.</p>
      </sec>
      <sec id="article-155735.s6" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Effective testing procedures for urine crystal identification and analysis are crucial for accurate diagnosis and patient care. Techniques commonly used for crystal analysis in clinical practice include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Standard light microscopy</p>
          </list-item>
          <list-item>
            <p>Optical polarization microscopy</p>
          </list-item>
          <list-item>
            <p>Automated microscopy</p>
          </list-item>
          <list-item>
            <p>Flow cytometry</p>
          </list-item>
          <list-item>
            <p>Digitalized microscopy</p>
          </list-item>
          <list-item>
            <p>Scanning electron microscopy</p>
          </list-item>
          <list-item>
            <p>Spectroscopy</p>
          </list-item>
        </list>
        <p>
<bold>Standard Light Microscopy</bold>
</p>
        <p>Manual direct microscopic examination&#x000a0;is the gold standard technique used in clinics to identify various urinary crystals based on their morphology.&#x000a0;When sufficiently trained and equipped, nephrologists can acquire important diagnostic information through direct microscopy. Brightfield microscopy is more commonly used compared to phase contrast microscopy, but phase contrast microscopy may be more beneficial for analyzing urine sediment.<xref ref-type="bibr" rid="article-155735.r6">[6]</xref><xref ref-type="bibr" rid="article-155735.r19">[19]</xref></p>
        <p>
<bold>Optical Polarization Microscopy</bold>
</p>
        <p>Polarized light microscopy is used to observe the color, morphology, and birefringence of crystals for identification. The color, refraction of the light, and double refraction are the parameters used in mineral identification. However, contaminants&#x000a0;can&#x000a0;sometimes&#x000a0;distort or interfere with the interpretations of results.<xref ref-type="bibr" rid="article-155735.r10">[10]</xref></p>
        <p>
<bold>Automated Microscopy</bold>
</p>
        <p>Automated microscopy is a method used in laboratory practice&#x000a0;that does not require urine centrifugation or standardized microscope measuring parameters. These machines are based on the Colter principle and became popular in hematology laboratory procedures in 1954 for the rapid and accurate enumeration of cells in the blood. They have been used for urine microscopy since the 1990s. Automated microscopy has been expanded to laser-based flow cytometry for better cell characterization.&#x000a0;&#x000a0;</p>
        <p>This technique can utilize a large sample size, reducing the laboratories' workload. Automated microscopy can deliver a complete urine analysis result if urinary biochemical data are combined and integrated with the microscopy analysis. The practical approach&#x000a0;is to use automated and manual machines to survey many specimens and expert microscopic examination for selected specimens. Automated systems have significant advantages over manual microscopy, as the specimens do not need centrifugation. They are also highly effective in diagnostic screening for blood, bacteria, and WBCs. However, automated systems significantly underperform in recognizing urinary casts and crystals compared to manual examinations performed by experienced lab technicians, pathologists, and nephrologists.<xref ref-type="bibr" rid="article-155735.r11">[11]</xref> The 2 major types of automated microscopy techniques are as follows:</p>
        <p>
<bold>Flow cytometry:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>These machines use laser-based flow cytometry with fluorescent dyes. Flow cytometry can reduce the need for microscopy or culture and is more useful in screening bacteriuria, pyuria, and hematuria, although sometimes microscopy is still required.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>This machine produces scattergrams, not actual images. Microscopy&#x000a0;is required to differentiate similar particles, such as various types of crystals, dysmorphic or isomorphic RBCs, and different types of epithelial cells. The advantage of this machine is that minimum expertise is required to operate it, and approximately&#x000a0;100 samples can be tested in&#x000a0;1 hour.<xref ref-type="bibr" rid="article-155735.r10">[10]</xref><xref ref-type="bibr" rid="article-155735.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Digitalized microscopy:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The digitalized microscopy technique uses computerized software to analyze digitalized monochrome images of urine particles. Two different instruments that supply digitized images are available. One is based on automated intelligent microscopy, which shows particles in the samples by categories&#x000a0;such as RBCs and WBCs. The other uses cuvette-based microscopy, which displays particles in the same way they appear in the microscopic field during manual examination.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A significant advantage of this technique is that it can be used for many samples and selective individual specimens. The images can be stored on a computer and sent to different sites, including other laboratories and clinics, for review by pathologists or nephrologists. In addition, this method is relatively cheaper compared to flow cytometry.<xref ref-type="bibr" rid="article-155735.r10">[10]</xref><xref ref-type="bibr" rid="article-155735.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Scanning Electron Microscopy</bold>
</p>
        <p>Scanning electron microscopy produces high-resolution images of the crystal surface, aiding in studying the morphology and texture of urinary calculi.&#x000a0;This method can analyze the characteristics of stones ranging from 1 mm to 5 mm without changing the morphology of their components,&#x000a0;and it does not destroy the stone sample. This method is also a proposed tool for diagnosing primary hyperoxaluria.</p>
        <p>
<bold>Spectroscopy</bold>
</p>
        <p>Spectroscopy identifies the molecular structure of a sample by investigating its interaction with electromagnetic radiation.&#x000a0;In this technique, infrared light passes through the sample, and the detector analyzes the intensity of the transmitted light. Vibrational spectroscopy identifies a sample's composition and molecular structure through its vibrational characteristics&#x000a0;when interacting with a beam source. This technique is analyzed based on the sample's vibrational characteristics when interacting with electromagnetic waves. Other spectroscopy methods, such as Raman and Fourier transform-infrared&#x000a0;spectroscopy,&#x000a0;are increasingly used in clinical practice.<xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p>These rapid, nondestructive, and relatively inexpensive methods&#x000a0;have been increasingly used in recent years to identify the chemical nature of urinary crystals and&#x000a0;detect organic matter.&#x000a0;Infrared spectroscopy is extremely useful in identifying calcium oxalate crystals.<xref ref-type="bibr" rid="article-155735.r21">[21]</xref></p>
        <p>Overall, clinicians should be able to identify most crystals by checking urine pH and urinalysis, then examining the urine sediment under bright field, phase contrast, and polarizing light microscopy. Fourier transform-infrared and Raman spectroscopy and solubility testing can be&#x000a0;additional resources for unclear crystal composition.<xref ref-type="bibr" rid="article-155735.r20">[20]</xref><xref ref-type="bibr" rid="article-155735.r22">[22]</xref></p>
      </sec>
      <sec id="article-155735.s7" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>The presence of urinary crystals associated with active urinary sediment, acute kidney injury, or kidney stones suggests a pathogenic process. Identifying and characterizing urinary crystals are essential for&#x000a0;diagnosing the type of stone, especially when the actual stone is not available for analysis (see <bold>Table 1.</bold> Characteristics of Commonly Observed Urinary Crystals). The results of urinary crystal analysis are reported after identifying various characteristics of urinalysis and microscopic examination of the urine sediment.</p>
        <p>
<bold>Commonly Reported Urinary Crystals</bold>
</p>
        <p><bold>Calcium oxalate crystals:&#x000a0;</bold>There are&#x000a0;2 significant types of calcium oxalate crystals&#x02014;monohydrate and dihydrate. The calcium oxalate&#x000a0;monohydrate (COM) crystals are&#x000a0;typically colorless on light microscopy. Their shape varies from oval, biconvex, and dumbbells to elongated rods (see <bold>Image.</bold>&#x000a0;Calcium Oxalate Monohydrate Crystals). These crystals are strongly birefringent on polarized microscopy.</p>
        <p>COD crystals are colorless on light microscopy and are bipyramidal or envelope-shaped, and their size is variable (see <bold>Image.</bold> Calcium Oxalate Dihydrate Crystals). These crystals&#x000a0;are non-birefringent on polarization. Calcium oxalate crystallization is commonly observed in the urine pH range of 5.0 to 6.5 and is rarely observed&#x000a0;when the urine pH increases to &#x0003e;7.0. A rare third form of calcium oxalate crystals, calcium oxalate trihydrate or caoxite, is hexagonal and seldom found in urine.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p><bold>Calcium phosphate crystals:&#x000a0;</bold>There are calcium orthophosphate crystals, mainly amorphous carbonated CaP and carbapatite, whereas brushite is dicalcium phosphate dihydrate.&#x000a0;</p>
        <p>CaP crystals are colorless on light microscopy. Calcium orthophosphate crystals are amorphous crystals that appear as small granulations with or without large plates and have no polarization (see&#x000a0;<bold>Image.</bold>&#x000a0;Amorphous Phosphate and Triple Phosphate Crystals in the Urine). Brushite crystals have a broad spectrum of shapes,&#x000a0;such as prisms, rosettes, starts, needle-like or splinter-like, or sticks or rods (see <bold>Image.</bold> Calcium Phosphate Crystals). These crystals are strongly birefringent on polarized microscopy and precipitate in alkaline urine.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p><bold>Struvite&#x000a0;or triple phosphate crystals:&#x000a0;</bold>These are radioopaque magnesium ammonium phosphate hexahydrate or triple phosphate crystals. Struvite crystals are colorless under light microscopy. The most common shape observed is a coffin lid; the other shapes are feather-like structures, elongated prisms, and trapezoids. These crystals are weak to strongly birefringent on polarization and precipitate in alkaline urine (see <bold>Images.</bold> Triple Phosphate Crystals; and Amorphous Phosphate and Triple Phosphate Crystals in the Urine).<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p><bold>Cystine crystals:&#x000a0;</bold>Cystine crystals are colorless on light microscopy and are either found alone or heaped onto&#x000a0;each other,&#x000a0;resembling perfect hexagonal plates. These crystals show weak birefringence on polarized microscopy and precipitate in urine with an acidic pH (see <bold>Image.</bold> Cystine Crystals in the Urinary Sediment).<xref ref-type="bibr" rid="article-155735.r18">[18]</xref>&#x000a0;Please see StatPearls' companion resource,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/20219">Cystinuria</ext-link>,"&#x000a0;for more information.</p>
        <p><bold>Uric acid and urate crystals:&#x000a0;</bold>There are&#x000a0;4 types of uric acid crystals in urine&#x02014;amorphous, anhydrous uric acid (uricite), monohydrate, and dihydrate crystals. Among these, uric acid dihydrate and amorphous uric acid crystals are most commonly observed.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p>Uric acid crystals are often amber-colored on light microscopy and have&#x000a0;various shapes, such as rho boards, barrels, rosettes, 4-sided plates, needles, rounds, or parallelograms. These&#x000a0;crystals show a very strong polychromatic birefringence on polarization (see&#x000a0;<bold>Images.</bold> Uric Acid Crystals, Barrel-Shaped; Uric Acid Crystals, Rosette-Shaped; and<bold>&#x000a0;</bold>Uric Acid Crystals, Birefringent on Polarized Light).&#x000a0;These crystals precipitate in urine with an acidic pH.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p><bold>Xanthine crystals:&#x000a0;</bold>Xanthine crystals&#x000a0;are&#x000a0;nonspecific in appearance and can be observed as polarized granules or sticks without a characteristic aspect. Crystal identification requires&#x000a0;infrared spectroscopy, high-pressure liquid chromatography, or chemical analysis of a xanthine stone. These crystals precipitate in urine with an acidic pH.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p><bold>Dihydroxyadenine crystals: </bold>DHA&#x000a0;crystals are somewhat brown or reddish-brown with a dark perimeter and central spicules that are round in shape on light microscopy. These crystals turn yellow and may demonstrate a characteristic birefringent Maltese-cross pattern on polarized microscopy. In suspected 2,8-DHA crystalluria, it is mandatory to investigate the crystals using infrared spectroscopy on a centrifuged pellet. These crystals precipitate in urine with an acidic or alkaline pH (4.8 to 9.0) and are relatively insoluble at any urinary pH.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <table-wrap id="article-155735.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Characteristics of Commonly Observed Urinary Crystals</title>
          </caption>
          <table style="width: 800px; float: left;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Crystal</bold></p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Morphology</bold></p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Birefringence</bold></p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Average pH (ranges)</bold>&#x000a0;</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Dependence on Urine pH</bold>&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Calcium oxalate monohydrate&#x000a0;</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless dumbbells, ovoids, rods</p>
<p>Elongated hexagonal shape (ethylene glycol poisoning)&#x000a0;</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>5.9 (4.8-7.5)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>Low</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Calcium oxalate dihydrate&#x000a0;</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless bipyramidal, rarely octahedral and dodecahedral&#x000a0;</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Weak</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>5.8 (4.8-7.5)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>Low</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Calcium phosphate (orthophosphates)&#x000a0;</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Amorphous round granulations</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Weak</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>6.7 (6.0-8.5)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>High</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Calcium phosphate (brushite)&#x000a0;</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Needles, sticks, rosettes, prisms</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>6.5 (5.9-8.0)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>High</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Struvite</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Coffin lids, prisms, trapezoids</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>7.7 (6.8-9.0)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>High</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Amorphous uric acid</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Amorphous, small, yellow, or red granulations</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>5.5 (4.7-6.5)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>Moderate</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Uric acid dihydrate</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Rhomboids, barrels, rosettes, needles, 6-sided plates</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong polychromatic</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>5.2 (4.7-6.3)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>High</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Xanthine</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Granules or sticks</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>5.6 (4.8-7.2)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>Moderate</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>2,8-Dihydroxyadenine</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Reddish-brown spherical</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Strong</p>
<p>Maltese cross</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>6.2 (4.8-9.0)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>Very low</p>
</td>
              </tr>
              <tr>
                <td style="width: 207px; border-color: black;" rowspan="1" colspan="1">
<p>Cystine</p>
</td>
                <td style="width: 214px; border-color: black;" rowspan="1" colspan="1">
<p>Hexagonal plates</p>
</td>
                <td style="width: 200px; border-color: black;" rowspan="1" colspan="1">
<p>Weak</p>
</td>
                <td style="width: 177.938px; border-color: black;" rowspan="1" colspan="1">
<p>6.8 (5.0-7.8)</p>
</td>
                <td style="width: 179.062px; border-color: black;" rowspan="1" colspan="1">
<p>Moderate</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Drug-Induced Crystals</bold>&#x000a0;</p>
        <p>Drug-induced urinary crystals are variable in size, shape, and other characteristics depending on the specific medication (see<bold> Table 2.</bold> Characteristics of Various Drug-Induced Crystals). These rare crystals comprise only 1% to 2% of all nephrolithiasis (see<bold> Images.&#x000a0;</bold>Sulfamethoxazole Crystals;<bold>&#x000a0;</bold>Sulfadiazine Crystals; and<bold>&#x000a0;</bold>Acyclovir Crystals).<xref ref-type="bibr" rid="article-155735.r7">[7]</xref></p>
        <table-wrap id="article-155735.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Characteristics of&#x000a0;Various Drug-Induced Crystals</title>
          </caption>
          <table style="width: 800px; float: left;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Drug Name</bold></p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p><bold>pH</bold></p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Color</bold></p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Shape</bold></p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p><bold>Polarization</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Sulfonamide</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Hexagon or ovoid</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>None</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Amoxicillin</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Thin needles or broom or brush-like</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Strongly birefringent</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Ciprofloxacin</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Alkaline</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Needles, star fans, or sheaves</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Strongly birefringent</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Triamterene</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Brown, green, orange, or red</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Spheres or unusual pleomorphism</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Maltese cross birefringence</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Sulfadiazine</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Amber</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Shocks or sheaves of wheat shells</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Strongly birefringent</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Methotrexate</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Yellow-Brown</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Thin needles</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Strongly birefringent</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Acyclovir</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Thin needles with sharp or blunt ends</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Strongly birefringent</p>
</td>
              </tr>
              <tr>
                <td style="width: 20px; border-color: black;" rowspan="1" colspan="1">
<p>Atazanavir</p>
</td>
                <td style="width: 65px; border-color: black;" rowspan="1" colspan="1">
<p>Acidic</p>
</td>
                <td style="width: 61px; border-color: black;" rowspan="1" colspan="1">
<p>Colorless</p>
</td>
                <td style="width: 106px; border-color: black;" rowspan="1" colspan="1">
<p>Needles in isolation or as aggregates&#x000a0;</p>
</td>
                <td style="width: 51.225px; border-color: black;" rowspan="1" colspan="1">
<p>Strongly birefringent</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Rare Crystals</bold>
</p>
        <p>Tyrosine crystals are colorless, thin, and needle-shaped, whereas leucine crystals are oval or round with circular striations. Both these crystals are found in acidic urine and are associated with aminoaciduria secondary to liver disease. Bilirubin crystals, which are clumped needles or yellow granules, are highly birefringent on polarization, and they are observed in conditions associated with hyperbilirubinemia. Cholesterol crystals are thin, transparent plates with cut edges. They are highly birefringent on polarization, typically observed&#x000a0;in association with nephrotic syndrome.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p>
<bold>Solubility Testing</bold>
</p>
        <p>The solubility test involves exposing the crystals to 10% KOH, 30% acetic acid, 30% HCL, and chloroform. The solubility of crystals in these fluids provides additional clues that aid in crystal identification (see <bold>Table 3.</bold> Solubility Characteristics of Crystals). This test is beneficial in identifying crystals with similar shapes.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref>&#x000a0;</p>
        <table-wrap id="article-155735.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3. Solubility Characteristics of Crystals</title>
          </caption>
          <table style="border-color: black; width: 800px; float: left;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 59px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p><bold>Crystal Type</bold></p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p><bold>Solubility in 10% KOH</bold></p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p><bold>Solubility in&#x000a0;</bold><bold>30% Acetic Acid</bold></p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p><bold>Solubility in&#x000a0;</bold><bold>30% HCL</bold></p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p><bold>Solubility in&#x000a0;</bold><bold>Chloroform</bold></p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Calcium oxalate</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Calcium phosphate</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Struvite</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Uric acid</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Bilirubin</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Cholesterol</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Cystine</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>2,8-Dihydroxyadenine</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes&#x000a0;</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No&#x000a0;</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Hippuric acid</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No data</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No data</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No data</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Leucine</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 59px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Tyrosine</p>
</td>
                <td style="height: 59px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 59px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 59px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
              </tr>
              <tr style="height: 31px;">
                <td style="height: 31px; width: 94.7523px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Xanthine</p>
</td>
                <td style="height: 31px; width: 93.2477px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>Yes</p>
</td>
                <td style="height: 31px; width: 85px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 31px; width: 95px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No</p>
</td>
                <td style="height: 31px; width: 65px; border-color: black; text-align: center;" rowspan="1" colspan="1">
<p>No data</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Interfering Factors&#x000a0;</bold>
</p>
        <p>Identifying urinary crystals can be challenging due to similarities in their shapes. Calcium sulfate, CaP, and sodium urate crystals can be needle-shaped or rectangle-shaped with blunt ends. COM, hippuric acid, uric acid, and ammonium biurate crystals can be rectangles with pointed ends. Amorphous urate and phosphate granules can have similar minor granular appearances. Solubility tests can help differentiate urinary crystals with similar shapes.<xref ref-type="bibr" rid="article-155735.r14">[14]</xref> Key considerations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Free hemosiderin granules are yellow-brown coarse granules that can be confused with amorphous phosphate and urate granules.</p>
          </list-item>
          <list-item>
            <p>2,8-DHA crystals can be confused with ammonium hydrogen urate as both have a small spherical shape.</p>
          </list-item>
          <list-item>
            <p>Starch granules are oval or round and highly refractive. Their irregular central indentation can resemble molar tooth grooves.</p>
          </list-item>
          <list-item>
            <p>Under polarized light,&#x000a0;starch granules can appear similar to a Maltese cross and be confused with 2,8-DHA crystals.</p>
          </list-item>
          <list-item>
            <p>Cholesterol and leucine crystals can also exhibit a typical Maltese-cross appearance under polarized light.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-155735.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Renal stone formation is always preceded by crystalluria, although the presence of urinary crystals does not always result in nephrolithiasis. Investigating crystalluria&#x000a0;is crucial for diagnosing and managing acute and chronic renal failure due to crystal precipitations associated with various inherited and acquired diseases. Identifying the type of urinary crystals is also helpful in offering specific targeted treatment for nephrolithiasis.</p>
        <p><bold>Calcium Oxalate Crystals</bold>&#x000a0;</p>
        <p>Calcium oxalate stones comprise up to 80% of all nephrolithiasis. Patients with calcium oxalate crystals should&#x000a0;be considered for primary and secondary causes of hyperoxaluria. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/154870">Calcium Deposition and Other Renal Crystal Diseases</ext-link>," for more information.&#x000a0;Calcium oxalate crystalluria is not necessarily pathologic, as these crystals can sometimes be found in those with high oxalate diets.<xref ref-type="bibr" rid="article-155735.r6">[6]</xref>&#x000a0;As an overview, calcium monohydrate crystals are generally associated with high urinary oxalate levels, calcium dihydrate crystals are generally associated with high urinary calcium, and the rare dodecahedral calcium dihydrate crystals are associated with very high urinary calcium.</p>
        <p>Secondary hyperoxaluria is much more common compared to primary hyperoxaluria and is often related to&#x000a0;1 of&#x000a0;3 mechanisms as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased dietary intake of oxalate-containing foods, such as peanuts, cashews, almonds, spinach, rhubarb, star fruit, chaga mushroom powder, and black iced tea.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased intestinal absorption of oxalate in a setting of fat malabsorption (enteric hyperoxaluria secondary to intestinal bypass surgery, short gut syndrome, Crohn disease, celiac disease, chronic pancreatitis, and orlistat).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased intake of oxalate precursors, such as ethylene glycol and vitamin C, can develop increased gut oxalate absorption, leading to excess urinary oxalate excretion. These patients are also at high risk&#x000a0;for&#x000a0;developing calcium oxalate crystalluria, crystalline nephropathy, chronic kidney disease, and end-stage kidney disease. Ingestion of the toxic substance, ethylene glycol, results in severe hyperoxaluria, and a very peculiar kind of monohydrate crystals&#x000a0;with elongated and narrow hexagonal shapes&#x000a0;similar to&#x000a0;diamonds are found in the urine.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>COD crystals are typically associated with hypercalciuria, such as hyperparathyroidism; hyperthyroidism; multiple myeloma; paraneoplastic syndrome; bone metastasis; vitamin D toxicity; particular drug use, including loop diuretics and vitamin-D supplements; and milk-alkali syndrome.</p>
        <p>According to Daudon et al, over 94% of urine specimens containing calcium oxalate crystals with a calcium-to-oxalate ratio of &#x0003c;5 show either monohydrate crystals alone or along with dihydrate crystals. In contrast, over 90% of urine specimens containing calcium oxalate crystals with a calcium-to-oxalate ratio &#x0003e;14 contain dihydrate crystals alone. Dodecahedral COD crystals typically indicate severe hypercalciuria, &#x0003e;7 mmol/L. All types of calcium-containing crystals are radioopaque.<xref ref-type="bibr" rid="article-155735.r8">[8]</xref><xref ref-type="bibr" rid="article-155735.r9">[9]</xref></p>
        <p>
<bold>Calcium Phosphate Crystals</bold>
</p>
        <p>Carbapatite crystals are typically observed&#x000a0;in patients with hypercalciuria on a background urine pH of 5.8 to 6.5. In contrast, amorphous CaP crystals are typically observed in patients with near-normal calcium and phosphate concentrations with a pH &#x0003e;6.6.<xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p>Amorphous CaP crystals suggest a possible environment created by urinary tract infections or metabolic disorders keeping the urine alkaline. When associated with the calcium monohydrate crystals, they indicate the presence of medullary sponge kidneys and other causes related to urinary stasis. When carbapatite crystals are associated with struvite crystals, they indicate the presence of urea-splitting organisms causing urinary tract infections.</p>
        <p>Brushite crystals are made of dicalcium phosphate dihydrate ions. These crystals&#x000a0;are mainly observed in conditions associated with marked hypercalciuria and hyperphosphaturia and are generally favored by low concentrations of citrates. The presence of &#x0003e;500/mL brushite crystals should prompt an evaluation for primary hyperparathyroidism. CaP crystals are radioopaque.<xref ref-type="bibr" rid="article-155735.r8">[8]</xref><xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p>
<bold>Struvite&#x000a0;Crystals</bold>
</p>
        <p>Struvite crystals are associated with high ammonium content and precipitate in alkaline urine. These crystals&#x000a0;are always associated with urinary tract infections by urea-splitting bacteria, where the bacteria hydrolyze the urea, producing ammonia and leading to alkaline urine. These bacteria are <italic toggle="yes">Klebsiella</italic>, <italic toggle="yes">Pseudomonas</italic>, <italic toggle="yes">Proteus</italic>, <italic toggle="yes">Providencia</italic>, and some species of <italic toggle="yes">Staphylococcus</italic>. These are radioopaque, sometimes&#x000a0;large enough to be called staghorn stones.<xref ref-type="bibr" rid="article-155735.r8">[8]</xref><xref ref-type="bibr" rid="article-155735.r9">[9]</xref><xref ref-type="bibr" rid="article-155735.r14">[14]</xref></p>
        <p><bold>Cystine Crystals</bold>&#x000a0;</p>
        <p>Cystine crystals are associated with hereditary cystinuria,&#x000a0;in which a proximal tubular dysfunction leads to increased excretion of dibasic amino acids such as cystine, ornithine, lysine, and arginine. Cystinuria is an autosomal recessive Mendelian disorder, and there are reports of acquired cystinuria post-renal transplant. Cystine forms radiolucent stones, which are not detected on x-rays but can be detected by ultrasound if the stones are large enough. CT scan is the gold standard for diagnosing renal stones and can detect cystine stones. Cystine becomes more soluble as the pH increases. The therapeutic urinary pH level to maximize solubility is &#x02265;7.5, typically higher compared to uric acid.<xref ref-type="bibr" rid="article-155735.r23">[23]</xref></p>
        <p><bold>Uric Acid Crystals</bold>&#x000a0;</p>
        <p>Uric acid crystals are associated with medical conditions leading to increased uric acid production or altered uric acid metabolism, such as gout, Lesch-Nyhan syndrome, tumor lysis, chemotherapy, or conditions associated with decreased urine pH, such as chronic diarrhea, metabolic syndrome, and diabetes mellitus. However, over half of patients with uric acid stones do not have hyperuricemia. These crystals&#x000a0;form radiolucent renal stones that are not detectable on x-rays&#x000a0;but can be&#x000a0;visualized on CT and ultrasound.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/keywords/cmeuserviewpopupwithquestions/167928?Return=%2FKeywords%2FIndex#link_30249419">[6]</ext-link></p>
        <p><bold>Xanthine Stones</bold>&#x000a0;</p>
        <p>Xanthine crystals are found in xanthinuria, a rare genetic disorder with autosomal recessive pattern inheritance caused by the deficiency of the enzyme xanthine dehydrogenase. This disorder leads to xanthine accumulation and highly insoluble xanthine excretion. Xanthinuria is associated with hypouricemia and hypouricosuria.<xref ref-type="bibr" rid="article-155735.r17">[17]</xref>&#x000a0;Rarely, xanthinuria can occur related to allopurinol use for Lesch-Nyan syndrome or tumor lysis syndrome.<xref ref-type="bibr" rid="article-155735.r24">[24]</xref>&#x000a0;More recently, the xanthine oxidase inhibitor, febuxostat, has also been noted to cause xanthinuria when used for tumor lysis syndrome.<xref ref-type="bibr" rid="article-155735.r25">[25]</xref></p>
        <p><bold>2,8-Dihydroxyadenine Crystals</bold>&#x000a0;</p>
        <p>2,8-DHA crystalluria is secondary to adenine phosphoribosyltransferase (APRT) deficiency, an autosomal recessive condition leading to excess DHA production, 2,8-DHA crystalluria, and kidney stones. The condition is underdiagnosed in the United States, with fewer than 300 cases reported in the medical literature. The worldwide prevalence is 1/5000 to 1/100,000 population. A significant number of patients remain asymptomatic, whereas 90% of patients develop urinary crystals and radiolucent renal stones. In addition, 10% of patients with 2,8-DHA crystalluria progress to end-stage renal failure. The diagnosis is confirmed by kidney stone analysis, histologic findings of crystal nephropathy, genetic testing, or lack of APRT activity in&#x000a0;RBC lysate. Treatment is recommended with allopurinol or febuxostat, which blocks the conversion of adenosine to DHA. The dosage should be titrated to eliminate 2,8-DHA crystalluria.<xref ref-type="bibr" rid="article-155735.r26">[26]</xref><xref ref-type="bibr" rid="article-155735.r27">[27]</xref></p>
        <p><bold>Drug-Induced Crystals</bold>&#x000a0;</p>
        <p>Drug-induced crystals are formed in association with the use of various drugs, as previously described. These crystals precipitate in the urine when used at a high dose, for long durations, or both. They form radiolucent renal stones when they contain no calcium or other radioopaque constituents. Patients experiencing signs and symptoms of nephrolithiasis while using these drugs should prompt the search for renal stones by ultrasound or contrast-enhanced CT imaging for diagnosis. Analyzing these crystals is crucial for identifying at-risk patients and clarifying the drugs or medications involved.<xref ref-type="bibr" rid="article-155735.r28">[28]</xref></p>
        <p><bold>Follow-Up</bold>&#x000a0;<bold>Monitoring</bold></p>
        <p>The complete disappearance of crystalluria is the best indicator of improved lithogenic activity in CaP, uric acid, and other common forms of nephrolithiasis. However, high-risk patients, such as those with cystinuria and PH1, can have active urinary crystallization even when the disease is under reasonable control.&#x000a0;</p>
        <p>Global crystal volume (GCV) helps determine lithogenicity in patients with crystalluria. GCV<bold>&#x000a0;</bold>is the product of the number of crystals/mm<sup>3</sup>&#x000a0;multiplied by the average size of crystals (in&#x000a0;&#x003bc;m) and by a numerical factor given for each crystal species (the numerical number is provided based on the geometrical form of a crystal). GCV of &#x0003c;500&#x000a0;&#x003bc;m<sup>3</sup>/mm<sup>3</sup> is associated with the lowest risk for tubular obstruction and crystalline nephropathy in patients with PH1. In patients with cystinuria, a GCV of &#x0003e;3000 &#x003bc;m<sup>3</sup>/mm<sup>3</sup>&#x000a0;is associated with an increased risk for recurrent nephrolithiasis.<xref ref-type="bibr" rid="article-155735.r9">[9]</xref></p>
      </sec>
      <sec id="article-155735.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinical outcomes can be significantly improved by emphasizing the importance of urine sediment examination and ensuring that medical students, residents, physician assistants, nurse practitioners, laboratory technicians, and other healthcare professionals receive comprehensive training on its routine application.</p>
        <p>The preanalytical phase is the most vulnerable part of the evaluation, accounting for up to 75% of all laboratory errors. Outcomes can be improved by following appropriate protocol-based patient preparation, obtaining mid-stream urine samples, rapid sample transportation, and preparation techniques. Nursing, lab processing, and transporting staff are crucial&#x000a0;in these collection steps. Physicians must often collect samples shortly before examination for the optimal specimens. Effective communication among team members is paramount. Conscientious laboratory staff are paramount in the accurate processing and calibration of microscopic and analytic equipment. Clear and open communication facilitates rapid diagnosis and treatment decisions, preventing errors and ensuring a coordinated interprofessional team response.</p>
      </sec>
      <sec id="article-155735.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=155735&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=155735">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/155735/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=155735">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-155735.s11">
        <fig id="article-155735.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Calcium Oxalate Monohydrate Crystals. The calcium oxalate monohydrate crystals are typically colorless on light microscopy, with shapes that vary from oval and biconvex to dumbbell and elongated rod forms. Contributed by R Naik, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="caoxmonohy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s12">
        <fig id="article-155735.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Calcium Oxalate Dihydrate Crystals. The calcium oxalate dihydrate crystals are colorless on light microscopy and have a bipyramidal or envelope shape. Contributed by R Naik, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="caox__dihy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s13">
        <fig id="article-155735.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Calcium Phosphate Crystals. Calcium phosphate crystals are colorless&#x000a0;on light microscopy. Brushite crystals have a broad spectrum of shapes, such as prisms, rosettes, starts, needle-like or splinter-like, sticks, or rods. Contributed by R Naik, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAlphoscrystal" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s14">
        <fig id="article-155735.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Triple Phosphate Crystals. Struvite crystals are colorless under light microscopy and often appear in distinctive coffin-lid shapes. Other shapes, such as feather-like structures, elongated prisms, and trapezoids, can also be observed. Contributed by R Naik, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="triplephos" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s15">
        <fig id="article-155735.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Amorphous Phosphate and Triple Phosphate Crystals in the Urine. Calcium orthophosphate crystals are amorphous crystals that appear as small granulations with or without large plates and have no polarization. Contributed by M Zubair, MBBS, FCPS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="A" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s16">
        <fig id="article-155735.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Uric Acid Crystals, Barrel-Shaped. The image shows barrel-shaped uric acid crystals on light microscopy. Contributed by R Naik, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="uric__acid2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s17">
        <fig id="article-155735.image.f7" position="float" orientation="portrait">
          <caption>
            <p>Uric Acid Crystals, Rosette-Shaped. The image shows rosette-shaped uric acid crystals on light microscopy. Iqbal Osman, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/wiki/File:Uric_acid_crystals_in_urine_sediment.jpg">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Uric__Acid__Crystals" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s18">
        <fig id="article-155735.image.f8" position="float" orientation="portrait">
          <caption>
            <p>Uric Acid Crystals, Birefringent on Polarized Light. Uric acid crystals&#x000a0;show a strong polychromatic birefringence on polarization. Contributed by S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="uric" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s19">
        <fig id="article-155735.image.f9" position="float" orientation="portrait">
          <caption>
            <p>Sulfamethoxazole Crystals. Urine sediment without staining &#x000d7;400. Left: bright field light microscopy;&#x000a0;right: polarized light microscopy. Seltzer J, Velez JC, Buchkremer F, Poloni JAT. Urine sediment of the month: drugs &#x00026; crystalluria. Renal Fellow Network Web site. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.renalfellow.org/2020/05/28/urine-sediment-of-the-month-drugs-crystalluria/">https://www.renalfellow.org/2020/05/28/urine-sediment-of-the-month-drugs-crystalluria/</ext-link>. Published May 28, 2020. Accessed May 20, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Sulfanamides__Crystals" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s20">
        <fig id="article-155735.image.f10" position="float" orientation="portrait">
          <caption>
            <p>Sulfadiazine Crystals. Unstained urine sediment &#x000d7;100. Left: bright field light microscopy;&#x000a0;right: polarized light microscopy. Seltzer J, Velez JC, Buchkremer F, Poloni JAT. Urine sediment of the month: drugs &#x00026; crystalluria<italic toggle="yes">.</italic> Renal Fellow Network Web site. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.renalfellow.org/2020/05/28/urine-sediment-of-the-month-drugs-crystalluria/">https://www.renalfellow.org/2020/05/28/urine-sediment-of-the-month-drugs-crystalluria/</ext-link>. Published May 28, 2020. Accessed May 20, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Sulfadiazine__Crystals" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-155735.s21">
        <fig id="article-155735.image.f11" position="float" orientation="portrait">
          <caption>
            <p>Acyclovir Crystals. Left: light microscopy unstained;&#x000a0;right: polarized light with birefringence. Seltzer J, Velez JC, Buchkremer F, Poloni JAT. Urine sediment of the month: drugs &#x00026; crystalluria. Renal Fellow Network Web site.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.renalfellow.org/2020/05/28/urine-sediment-of-the-month-drugs-crystalluria/"> https://www.renalfellow.org/2020/05/28/urine-sediment-of-the-month-drugs-crystalluria/</ext-link>. Published May 28, 2020. Accessed May 20, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Acyclcovir__crystals" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-155735.s22">
        <title>References</title>
        <ref id="article-155735.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorokin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mamoulakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miyazawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of stone disease across the world.</article-title>
            <source>World J Urol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1301</fpage>
            <page-range>1301-1320</page-range>
            <pub-id pub-id-type="pmid">28213860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narendrula</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El-Zawahry</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sindhwani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ekwenna</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study Data.</article-title>
            <source>Eur Urol Open Sci</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>35</volume>
            <fpage>37</fpage>
            <page-range>37-46</page-range>
            <pub-id pub-id-type="pmid">35024630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chewcharat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Trends in the prevalence of kidney stones in the United States from 2007 to 2016.</article-title>
            <source>Urolithiasis</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-39</page-range>
            <pub-id pub-id-type="pmid">32870387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Couto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dos Santos</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin Crystalluria: A Rare Side-Effect of a Commonly Prescribed Antibiotic.</article-title>
            <source>Eur J Case Rep Intern Med</source>
            <year>2017</year>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>000736</fpage>
            <pub-id pub-id-type="pmid">30755915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verdesca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fogazzi</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Garigali</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daudon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Crystalluria: prevalence, different types of crystals and the role of infrared spectroscopy.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-20</page-range>
            <pub-id pub-id-type="pmid">21143023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavanaugh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-272</page-range>
            <pub-id pub-id-type="pmid">30249419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shastri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sambandam</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>82</volume>
            <issue>5</issue>
            <fpage>617</fpage>
            <page-range>617-634</page-range>
            <pub-id pub-id-type="pmid">37565942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Recent advances on the mechanisms of kidney stone formation (Review).</article-title>
            <source>Int J Mol Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">34132361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frochot</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Daudon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi.</article-title>
            <source>Int J Surg</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>Pt D</issue>
            <fpage>624</fpage>
            <page-range>624-632</page-range>
            <pub-id pub-id-type="pmid">27847293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogazzi</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Crystalluria: a neglected aspect of urinary sediment analysis.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>379</fpage>
            <page-range>379-87</page-range>
            <pub-id pub-id-type="pmid">8671802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00130;nce</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Ellida&#x0011f;</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Koseo&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x0015e;im&#x0015f;ek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yal&#x000e7;&#x00131;n</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zengin</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The comparison of automated urine analyzers with manual microscopic examination for urinalysis automated urine analyzers and manual urinalysis.</article-title>
            <source>Pract Lab Med</source>
            <year>2016</year>
            <month>Aug</month>
            <day>01</day>
            <volume>5</volume>
            <fpage>14</fpage>
            <page-range>14-20</page-range>
            <pub-id pub-id-type="pmid">28856199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Colona</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hoenig</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lundquist</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Waikar</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Interobserver Reliability of Nephrologist Examination of Urine Sediment.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Aug</month>
            <day>03</day>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>e2013959</fpage>
            <pub-id pub-id-type="pmid">32821922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Letavernier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bazin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Daudon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Description of Stone Morphology and Crystalluria Improve Diagnosis and Care of Kidney Stone Formers.</article-title>
            <source>Healthcare (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>20</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36611462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Differential identification of urine crystals with morphologic characteristics and solubility test.</article-title>
            <source>J Clin Lab Anal</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>e24707</fpage>
            <pub-id pub-id-type="pmid">36164743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagae</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hiwada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kono</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic hereditary xanthinuria: a case report.</article-title>
            <source>Jpn J Med</source>
            <year>1990</year>
            <season>May-Jun</season>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-91</page-range>
            <pub-id pub-id-type="pmid">2273608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amaya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishino</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.</article-title>
            <source>Int J Mol Sci</source>
            <year>2012</year>
            <month>Nov</month>
            <day>21</day>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>15475</fpage>
            <page-range>15475-95</page-range>
            <pub-id pub-id-type="pmid">23203137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grases</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Costa-Bauza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Xanthine urolithiasis: Inhibitors of xanthine crystallization.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e0198881</fpage>
            <pub-id pub-id-type="pmid">30157195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadiq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cil</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Cystinuria: An Overview of Diagnosis and Medical Management.</article-title>
            <source>Turk Arch Pediatr</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>377</fpage>
            <page-range>377-384</page-range>
            <pub-id pub-id-type="pmid">35822468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogazzi</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Delanghe</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Microscopic examination of urine sediment: Phase contrast versus bright field.</article-title>
            <source>Clin Chim Acta</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>487</volume>
            <fpage>168</fpage>
            <page-range>168-173</page-range>
            <pub-id pub-id-type="pmid">30287257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Kidney stone analysis techniques and the role of major and trace elements on their pathogenesis: a review.</article-title>
            <source>Biophys Rev</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>3-4</issue>
            <fpage>291</fpage>
            <page-range>291-310</page-range>
            <pub-id pub-id-type="pmid">28510032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steenbeke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boelens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oyaert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glorieux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van Biesen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Linjala</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Delanghe</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Speeckaert</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Exploring the possibilities of infrared spectroscopy for urine sediment examination and detection of pathogenic bacteria in urinary tract infections.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2020</year>
            <month>Sep</month>
            <day>25</day>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>1759</fpage>
            <page-range>1759-1767</page-range>
            <pub-id pub-id-type="pmid">32649292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Imran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Talati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jafri</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fourier transform infrared spectroscopy for analysis of kidney stones.</article-title>
            <source>Investig Clin Urol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-37</page-range>
            <pub-id pub-id-type="pmid">29333512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simhadri</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Vaitla</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Marathi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Donor-transmitted cystinuria in a renal transplant recipient.</article-title>
            <source>J Nephrol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">38512367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaRosa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McMullen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bakdash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Acute renal failure from xanthine nephropathy during management of acute leukemia.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <page-range>132-5</page-range>
            <pub-id pub-id-type="pmid">17039332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Yoshizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sekiguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murahashi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Toda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Umino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minakata</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ashizawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hatano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohmine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanda</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome.</article-title>
            <source>Intern Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>01</day>
            <volume>61</volume>
            <issue>21</issue>
            <fpage>3271</fpage>
            <page-range>3271-3275</page-range>
            <pub-id pub-id-type="pmid">35370238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Runolfsdottir</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Palsson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agustsdottir</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Indridason</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Edvardsson</surname>
                <given-names>VO</given-names>
              </name>
            </person-group>
            <article-title>Kidney Disease in Adenine Phosphoribosyltransferase Deficiency.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>431</fpage>
            <page-range>431-8</page-range>
            <pub-id pub-id-type="pmid">26724837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Milliner</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Boelkins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Broviac</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fidler</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>1909</fpage>
            <page-range>1909-15</page-range>
            <pub-id pub-id-type="pmid">20064951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-155735.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Herlitz</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>The Crystalline Nephropathies.</article-title>
            <source>Kidney Int Rep</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>12</issue>
            <fpage>2942</fpage>
            <page-range>2942-2957</page-range>
            <pub-id pub-id-type="pmid">34901567</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
